Paul Owen

Paul Owen has been the Kailos Genetics Chief Business Officer and COO since June 2020. Prior to Kailos he was the CEO of OneOme, an innovator in precision medicine and pharmacogenetics, co-founded by Mayo Clinic. Paul joined OneOme in 2015 and lead his team in the effort to empower smarter prescription decisions through OneOme’s RightMed® medication optimization platform. While leading OneOme they were recognized by Fast Company as top 22 of 50 most innovative companies in the world, #2 in biotech.

Prior to joining OneOme Paul led global commercialization for Invitae, a San Francisco-based fast-growing hereditary disease diagnostics company that raised over $120Million in capital during Paul’s tenure. Previously, Paul served as Vice Chair of Global Business Development for Mayo Clinic and was the leader of Mayo Medical Laboratories’ global commercial team. Prior to that, Paul held leadership roles at what is now Zimmer-Biomet and at Boston Scientific.

Paul also serves on the Boards of Directors for OpalGenix, The Redemption Project, and Humanitarian Medical. He is a former Board member and now Executive Advisor to Phenomix Sciences. He is also an advisor for the University of Minnesota Ventures Business Group and the gBETA MedTech Accelerator. Paul received his B.S. in business administration from the University of Wisconsin – Stout.